US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
We have updated Multiple Sclerosis Drugs Market with respect to COVID-19 Business Impact. Inquire before buying This report focuses on the Multiple Sclerosis Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Multiple Sclerosis Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.
Global Multiple Sclerosis Drugs Market: Segment AnalysisThe research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.
Global Multiple Sclerosis Drugs Market: Regional AnalysisThe research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.
Global Multiple Sclerosis Drugs Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Other players
Report CoverageMultiple Sclerosis is an immune-mediated disease of the central nervous system and one of the most common neurological disorders. According to the European Multiple Sclerosis Platform (EMSP), approximately 762,760 people in Europe were estimated to have multiple sclerosis in 2015. The increasing prevalence and global burden of the disease have triggered many pharmaceutical giants for the development of novel multiple sclerosis drugs. Most of the commercially available drugs are Disease Modifying Drugs (DMDs) which are effective for the treatment of relapsing multiple sclerosis. Presence of limited treatment options, high drug cost, proactive government initiatives are the factors which are poised to surge the demand for multiple sclerosis drugs. The report provides qualitative and quantitative insights on the multiple sclerosis drugs industry and detailed analysis of the global multiple sclerosis drugs market size and growth rate for all possible segments in the market. The market is segmented by drug class, route of administration, and distribution channel. Based on drug class, the global multiple sclerosis drugs market is segmented into immunomodulators, immunosuppressants, interferons, and others. In terms of route of administration, the market is categorized into oral and injection. The injection segment can be further classified into intramuscular, subcutaneous and intravenous. The distribution channels which are covered under the report are hospital pharmacy, retail pharmacy, and online stores. Geographically, the market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further categorized into countries. Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of multiple sclerosis, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, new product launch, pipeline analysis, patent analysis, and key industry trends.
By Drug Class
By Route of Administration
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Key Industry Developments
In October 2020,Accord Healthcare S.L.U. received marketing authorisation valid throughout the European Union for Fampridine Accord which is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. MS is a disease in which the immune system (the body’s defences) attacks and damages the covering around the nerves and the nerves themselves in the brain and spinal cord. Fampridine Accord is a ‘generic medicine’. This means that Fampridine Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Fampyra. Fampridine Accord contains the active substance fampridine. Fampridine is a board-spectrum lipophillic potassium channel blocker and binds favourably to the open state than closed state of the potassium channel in the CNS. Its pharmacological target are the potassium channels exposed in MS patients and does not prolong the QTc interval. Fampridine Accord has been shown to have comparable quality and to be bioequivalent to Fampyra. Therefore, the Agency’s view was that, as for Fampyra, the benefits of Fampridine Accord outweigh the identified risks and it can be authorised for use in the EU.
In March 2019,Novartis AG announced the FDA approval for Mayzent, an immunomodulator for the treatment of relapsing forms of multiple sclerosis (RMS).
In January 2018,Eisai Co., Ltd. collaborated with Biogen for the co-promotion of TECFIDERA, TYSABRI, and AVONEX in Japan.
In March 2017,F. Hoffmann-La Roche Ltd received the FDA approval for Ocrevus for the treatment of adult patients having relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
In February 2017,Apitope, a company for drug discovery and development announced positive results from the Phase IIa clinical study of the companys multiple sclerosis drug candidate named ATX-MS-1467.
Table of Content Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions 1.3. List of Data Sources Chapter 2. Executive Summary Chapter 3. Multiple Sclerosis Drugs Market 3.1. Market Segmentation 3.2. Market Size and Growth Prospects, 2019 - 2029 3.3. Value Chain Analysis 3.4. Market Dynamics 3.4.1. Market driver analysis 3.4.2. Market restraint analysis Chapter 4. Market Size by Application 4.1 Multiple Sclerosis Drugs Market Consumption by Application (2015-2020) 4.2 Multiple Sclerosis Drugs Market Consumption by Application (2020-2029) | read more...